A. Sucker

D. Schadendorf, A. Bankfalvi, E. Livingstone, 2019, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

Inherited functional variants of the lymphocyte receptor CD5 influence melanoma survival

D. Schadendorf, J. Malvehy, S. Puig, 2016, International journal of cancer.

Evolution of melanoma cross-resistance to CD8+ T cells and MAPK inhibition in the course of BRAFi treatment

S. Haferkamp, D. Schadendorf, B. Schilling, 2018, Oncoimmunology.

The Prognostic Relevance of PMCA4 Expression in Melanoma: Gender Specificity and Implications for Immune Checkpoint Inhibition

D. Schadendorf, B. Győrffy, A. Bankfalvi, 2022, International journal of molecular sciences.

Inherited variation in the PARP1 gene and survival from melanoma

Dirk Schadendorf, Susana Puig, Johan Hansson, 2014, International journal of cancer.

Targeted massively parallel sequencing of angiosarcomas reveals frequent activation of the mitogen activated protein kinase pathway

Donavan T. Cheng, D. Schadendorf, B. Schilling, 2015, Oncotarget.

Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis.

D. Schadendorf, C. Garbe, G. Pawelec, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Melanoma Lesions Independently Acquire T-cell Resistance during Metastatic Latency.

D. Schadendorf, J. Becker, A. Roesch, 2016, Cancer research.

STAT3 Single Nucleotide Polymorphism rs4796793 SNP Does Not Correlate with Response to Adjuvant IFNα Therapy in Stage III Melanoma Patients

D. Schadendorf, J. Becker, S. Ugurel, 2014, Front. Med..

Characterisation and outcome of RAC1 mutated melanoma.

M. Weichenthal, J. Utikal, D. Schadendorf, 2023, European journal of cancer.

Integrin genes and susceptibility to human melanoma.

D. Schadendorf, K. Hemminki, Rajiv Kumar, 2012, Mutagenesis.

Circulating CD4+ T Cells That Produce IL4 or IL17 When Stimulated by Melan-A but Not by NY-ESO-1 Have Negative Impacts on Survival of Patients with Stage IV Melanoma

D. Schadendorf, C. Garbe, G. Pawelec, 2014, Clinical Cancer Research.

Biology of Human Tumors Circulating CD 4 þ T Cells That Produce IL 4 or IL 17 When Stimulated by MelanA but Not by NY-ESO-1 Have Negative Impacts on Survival of Patients with Stage IV Melanoma

D. Schadendorf, G. Pawelec, M. Maio, 2014 .

Liquid Profiling of Circulating Tumor DNA in Plasma of Melanoma Patients for Companion Diagnostics and Monitoring of BRAF Inhibitor Therapy.

J. Utikal, D. Schadendorf, T. Holland-Letz, 2018, Clinical chemistry.

Glucocorticoid activation by HSD11B1 limits T cell-driven interferon signaling and response to PD-1 blockade in melanoma

D. Schadendorf, J. Marine, F. Rambow, 2023, Journal for ImmunoTherapy of Cancer.

NF1 mutations in conjunctival melanoma

D. Schadendorf, B. Schilling, C. Franklin, 2018, British Journal of Cancer.

Conjunctival Melanomas Harbor BRAF and NRAS Mutations—Response

D. Schadendorf, B. Schilling, E. Livingstone, 2013, Clinical Cancer Research.

BRAF inhibitor acquired resistance: A multicenter meta-analysis of the spectrum and clinical implications of resistance mechanisms.

D. Schadendorf, L. Garraway, J. Sosman, 2015 .

Role of Elevated PHIP Copy Number as a Prognostic and Progression Marker for Cutaneous Melanoma

D. Schadendorf, A. Lazar, J. Gershenwald, 2018, Clinical Cancer Research.

Deciphering the genetic evolution of T-cell resistance in melanoma

A. Sucker, A. Paschen, 2015, Oncoimmunology.

Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma

J. Utikal, D. Schadendorf, W. Sondermann, 2023, Nature Cancer.

Frequent Occurrence of NRAS and BRAF Mutations in Human Acral Naevi

J. Klode, D. Schadendorf, P. Jansen, 2019, Cancers.

Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma – analysis of the DeCOG prospective multicenter cohort study ADOREG/TRIM

M. Weichenthal, J. Utikal, J. Klode, 2023, EBioMedicine.

Tumor PD-L1 expression and gene panel mutational profile as outcome predictors of PD-1-based checkpoint inhibition therapy in metastatic melanoma: A prospective multicenter DeCOG study.

M. Weichenthal, J. Utikal, D. Schadendorf, 2021 .

Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma.

J. Utikal, C. Berking, D. Schadendorf, 2014 .

TERT Promoter Mutations in Familial and Sporadic Melanoma

D. Schadendorf, K. Hemminki, Rajiv Kumar, 2013, Science.

Interferon‐γ down‐regulates NKG2D ligand expression and impairs the NKG2D‐mediated cytolysis of MHC class I‐deficient melanoma by natural killer cells

D. Schadendorf, Sonja Textor, A. Cerwenka, 2009, International journal of cancer.

Melanoma genome sequencing reveals frequent PREX2 mutations

Trevor J Pugh, T. Fennell, A. Sivachenko, 2012, Nature.

Complete loss of HLA class I antigen expression on melanoma cells: A result of successive mutational events

D. Schadendorf, F. Garrido, A. Sucker, 2003, International journal of cancer.

High mobility group box 1 is increased in the sera of psoriatic patients with disease progression

H. Koenen, A. Sucker, L. Strohbuecker, 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.

Metalloprotease-mediated tumor cell shedding of B7-H6, the ligand of the natural killer cell-activating receptor NKp30.

P. Altevogt, S. Rose-John, Sonja Textor, 2014, Cancer research.

Characterisation and outcome of RAC1 mutated melanoma.

M. Weichenthal, J. Utikal, D. Schadendorf, 2023, European journal of cancer.

Atypical fibroxanthoma and pleomorphic dermal sarcoma harbor frequent NOTCH1/2 and FAT1 mutations and similar DNA copy number alteration profiles

D. Schadendorf, C. Franklin, R. Murali, 2018, Modern Pathology.

HLA class II loss and JAK1/2 deficiency coevolve in melanoma leading to CD4 T cell and IFNγ cross-resistance.

D. Schadendorf, S. Ferrone, A. Roesch, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.

Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- ("Triple") wild type melanomas.

A. Sucker, F. Meier, A. Paschen, 2024, European journal of cancer.

Analysis of SDHD promoter mutations in various types of melanoma

W. Sondermann, A. Sucker, S. Horn, 2015, Oncotarget.

Application of Circulating Cell-Free Tumor DNA Profiles for Therapeutic Monitoring and Outcome Prediction in Genetically Heterogeneous Metastatic Melanoma.

D. Schadendorf, J. Becker, A. Stang, 2019, JCO precision oncology.

Early versus late response to PD-1-based immunotherapy in metastatic melanoma.

P. Jansen, A. Sucker, B. Hellwig, 2024, European journal of cancer.

Single-cell RNA and T-cell receptor sequencing unveil mycosis fungoides heterogeneity and a possible gene signature

A. Sucker, Farnoush Farahpour, Nalini Srinivas, 2024, Frontiers in Oncology.